SCHEMBL524140

SCHEMBL524140

O=C(O)CC(CC(CC(=O)O)C(=O)O)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.62
TDP1 Q9NUW8 2/20 0.53
CPA1 P15085 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CPB1 P15086 1/20 0.50
CPA3 P15088 1/20 0.50
CPB2 Q96IY4 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.47
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43
CHRM1 P11229 1/20 0.41
AKR1A1 P14550 1/20 0.41
CHRM3 P20309 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14591440 1.00 FOLH1 (0.62) FOLH1TDP1CPA1SMN1; SMN2CPB1
Hydrochloric Acid SCHEMBL8841246 0.97 FOLH1 (0.59) FOLH1TDP1CPA1SMN1; SMN2CPB1
SCHEMBL270456 0.97 FOLH1 (0.67) FOLH1TDP1CPA1SMN1; SMN2CPB1
SCHEMBL1451353 0.91 FOLH1 (0.54) FOLH1TDP1CPA1SMN1; SMN2CPB1
Tricarballylic Acid SCHEMBL1821947 0.90 FOLH1 (0.65) FOLH1TDP1CPA1SMN1; SMN2CPB1
Tricarballylic Acid SCHEMBL34866 0.90 FOLH1 (0.65) FOLH1TDP1CPA1SMN1; SMN2CPB1
SCHEMBL27199098 0.89 SLC22A6 (0.52) FOLH1TDP1CPA1SMN1; SMN2CPB1
Tricarballylic Acid SCHEMBL11728494 0.87 FOLH1 (0.62) FOLH1TDP1CPA1SMN1; SMN2CPB1
Tricarballylic Acid SCHEMBL8329654 0.87 FOLH1 (0.62) FOLH1TDP1CPA1SMN1; SMN2CPB1
Tricarballylic Acid SCHEMBL6757051 0.87 FOLH1 (0.62) FOLH1TDP1CPA1SMN1; SMN2CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115893344-B Method for preparing zinc phosphate from zinc-containing minerals 南京铜锌源环保科技有限公司 2024-07-16 CN claimed
EP-3143067-B1 MULTIFUNCTIONAL POLYAMIDES FOR PROTECTIVE COATINGS HUNTSMAN ADVANCED MAT AMERICAS LLC (US) 2023-09-13 EP claimed
CN-115893344-A Method for preparing zinc phosphate from zinc-containing mineral 南京铜锌源环保科技有限公司 2023-04-04 CN claimed
CN-114315788-A Preparation method of lactide 普立思生物科技有限公司 2022-04-12 CN claimed
CN-105408811-B Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same 日产化学工业株式会社 2019-01-15 CN claimed
WO-2018115011-A1 GLYCOLIC ACID POLYMER COMPOSITION SOLVAY SA (BE) 2018-06-28 WO claimed
EP-3339372-A1 GLYCOLIC ACID POLYMER COMPOSITION Solvay SA (BE) 2018-06-27 EP claimed
US-20160108174-A1 POLYAMIDES COMPRISING ME-BHT, COMPOSITIONS COMPRISING SUCH A POLYAMIDE, SHAPED ARTICLES COMPRISING SUCH A POLYAMIDE OR SUCH A COMPOSITION PERFORMANCE POLYAMIDES, SAS (FR) 2016-04-21 US claimed
EP-3004210-A1 POLYAMIDES COMPRISING ME-BHT, COMPOSITIONS COMPRISING SUCH A POLYAMIDE, SHAPED ARTICLES COMPRISING SUCH A POLYAMIDE OR SUCH A COMPOSITION Rhodia Opérations S.A.S. (FR) 2016-04-13 EP claimed
CN-105431471-A Polyamides comprising ME-BHT, compositions comprising such a polyamide, shaped articles comprising such a polyamide or such a composition RHODIA OPERATIONS 2016-03-23 CN claimed
WO-2004035671-A1 FLAME RETARDANT COMPOSITIONS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-04-29 WO claimed
WO-2003050175-A2 FLAME RETARDANT CONPOSITIONS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-06-19 WO claimed
US-6403681-B2 STABILIZER FOR PLASTICS CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-11 US claimed
US-20020040145-A1 Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith GALBO JAMES P (US) 2002-04-04 US claimed
US-20010034449-A1 Hydroxy-substituted N-Alkoxy hindered amines and compositions stabilized therewith GALBO JAMES P (US) 2001-10-25 US claimed
US-20010031872-A1 Hydroxy-substituted N-Alkoxy hindered amines and compositions stabilized therewith GALBO JAMES P (US) 2001-10-18 US claimed
US-20010020099-A1 Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith GALBO JAMES P (US) 2001-09-06 US claimed
US-20010018520-A1 Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith GALBO JAMES P (US) 2001-08-30 US claimed
US-5616249-A USING ALL ALIPHATIC POLYAMIDES FROM POLYAMINO COMPOUNDS AND COMPOUNDS HAVING TWO OR MORE ACID HALIDE GROUPS IONICS, INCORPORATED (US) 1997-04-01 US claimed
US-4831134-A N-hydroxy hindered amine stabilizers CIBA-GEIGY CORPORATION (US) 1989-05-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040145-A1 Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith POLH, OGG1, OGFOD1 FOLH1 2945/4885TDP1 606/4885CPA1 4604/4885
US-20010034449-A1 Hydroxy-substituted N-Alkoxy hindered amines and compositions stabilized therewith POLH, OGG1, OGFOD1 FOLH1 2945/4885TDP1 606/4885CPA1 4604/4885
US-20010020099-A1 Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith POLH, OGG1, OGFOD1 FOLH1 2945/4885TDP1 606/4885CPA1 4604/4885
US-20010018520-A1 Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith POLH, OGG1, OGFOD1 FOLH1 2945/4885TDP1 606/4885CPA1 4604/4885
US-20010031872-A1 Hydroxy-substituted N-Alkoxy hindered amines and compositions stabilized therewith POLH, OGG1, OGFOD1 FOLH1 2945/4885TDP1 606/4885CPA1 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.